- This combo delays cancer growth in hard-to-treat cases
- Helps patients who’ve run out of options
- Still in trials — not yet available everywhere
This could give more time to people with advanced bladder cancer.
For years, Mark, 64, thought he’d beaten cancer. Then came the scan that changed everything. The disease had returned — aggressive, spreading, and resistant to the drugs he’d already tried. Like thousands of others, he faced a grim choice: limited treatments, shrinking hope. But now, a new approach is offering a fresh path forward.
Bladder cancer isn’t rare. And when it spreads, it’s called advanced urothelial carcinoma (aUC). That’s the most common type of bladder cancer. About 20,000 people in the U.S. die from it each year. After first-line treatment fails, options become slim. Some patients don’t respond to immunotherapy. Others relapse quickly. Doctors have been searching for something that works — and works longer.
For a long time, chemo was the only backup plan. But results were short-lived. Immunotherapy helped some — but not most.
Then came a new idea: what if we combine immunotherapy with chemo in a smarter way?
The surprising shift
Camrelizumab is a type of immunotherapy. It’s a drug that helps the body’s immune system “see” cancer cells. Think of it like taking the brakes off immune cells. Nab-paclitaxel is a chemo drug. It attacks fast-growing cancer cells. It’s already used in breast and lung cancers.
Doctors wondered: could these two work better together?
But here’s the twist — most experts thought combining them might be too toxic. Too hard on the body. What’s different this time? The dose and timing.
Patients got camrelizumab once every three weeks. Then nab-paclitaxel on day one and day eight of each cycle. This staggered plan may reduce side effects — while keeping the punch.
Imagine cancer cells wearing invisibility cloaks. Camrelizumab rips off the cloak. Now the immune system can spot and attack.
But cancer is sneaky. It also builds walls — like a fortress. Nab-paclitaxel breaks through those walls. Together, they hit cancer from two sides.
It’s like sending in special forces while also cutting off enemy supply lines.
The study followed 60 patients across multiple cancer centers. All had advanced bladder cancer that came back after first treatment. Some had already tried immunotherapy — and it failed. They got the combo every 21 days until the cancer worsened or side effects became too severe.
On average, patients lived without their cancer getting worse for 4.7 months. That may not sound like much — but for this group, it’s meaningful progress.
And overall, patients lived an average of 15.7 months after starting treatment. For some, it was much longer. 15 people had responses that lasted over a year. That’s rare in this stage of cancer.
One in three patients saw their tumors shrink. That’s called an objective response. Four patients had no detectable cancer after treatment — a complete response.
This doesn’t mean this treatment is available yet.
But there’s a catch.
Nearly everyone had side effects. Most were manageable — fatigue, nausea, low blood counts. But more than half had serious ones, like severe infections or nerve damage. One patient developed immune-related pneumonia — a known risk with this type of drug.
Still, doctors say the balance of benefit and risk looks promising.
What scientists didn’t expect
Researchers also tested blood samples before treatment. They were looking for clues — biomarkers — to predict who would respond best.
Three stood out: CD25, IL-6, and IGFBP-2. Patients with high levels of these proteins had worse outcomes.
This could one day help doctors choose the right patients — and avoid giving tough treatments to those unlikely to benefit.
Today, many patients with relapsed bladder cancer face a dead end. No standard second-line therapy works for everyone. Some get chemo. Others try new drugs in trials.
This combo isn’t a cure. But it could become a new option — especially for those who’ve tried everything else.
Experts say the survival numbers are modest but encouraging. “The fact that some responses lasted over a year is noteworthy,” said one oncologist not involved in the study. “We don’t see that often in this setting.”
If you or a loved one has advanced bladder cancer that came back after treatment, this approach may be worth discussing with your doctor — especially if other options are limited.
But it’s not available outside of clinical trials right now. The study was small and early-phase. More research is needed before it becomes standard care.
Ask your oncologist if you might qualify for ongoing trials. Location, past treatments, and overall health all matter.
The hidden hurdle
The study only included 60 people. That’s too small to prove this works for everyone. Also, there was no comparison group — meaning we don’t know if this combo is better than chemo alone.
Most participants were Chinese — so results may differ in other populations. And while survival improved for some, not everyone benefited.
Larger phase III trials are needed — and likely underway. Those studies will compare this combo to current standard treatments. They’ll also dig deeper into the blood biomarkers to personalize therapy.
For now, this is a step — not a finish line. But for patients running out of time, even a small step can mean a lot.
